CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Taysha Gene Therapies, Inc. - TSHA CFD

    1.76
    4.14%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Taysha Gene Therapies Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.69
    Open* 1.69
    1-Year Change* -16.75%
    Day's Range* 1.67 - 1.77
    52 wk Range 0.50-3.89
    Average Volume (10 days) 4.19M
    Average Volume (3 months) 59.39M
    Market Cap 325.31M
    P/E Ratio -100.00K
    Shares Outstanding 186.96M
    Revenue 14.35M
    EPS -2.58
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Mar 26, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 1.76 0.13 7.98% 1.63 1.77 1.63
    Dec 7, 2023 1.69 0.06 3.68% 1.63 1.70 1.49
    Dec 6, 2023 1.68 -0.08 -4.55% 1.76 1.80 1.66
    Dec 5, 2023 1.75 -0.03 -1.69% 1.78 1.80 1.72
    Dec 4, 2023 1.80 -0.03 -1.64% 1.83 1.84 1.71
    Dec 1, 2023 1.82 0.10 5.81% 1.72 1.82 1.63
    Nov 30, 2023 1.75 -0.02 -1.13% 1.77 1.84 1.71
    Nov 29, 2023 1.79 0.02 1.13% 1.77 1.85 1.75
    Nov 28, 2023 1.77 0.03 1.72% 1.74 1.82 1.71
    Nov 27, 2023 1.77 -0.08 -4.32% 1.85 1.86 1.72
    Nov 24, 2023 1.86 0.09 5.08% 1.77 1.89 1.77
    Nov 22, 2023 1.80 0.09 5.26% 1.71 1.81 1.70
    Nov 21, 2023 1.71 0.01 0.59% 1.70 1.77 1.65
    Nov 20, 2023 1.77 0.09 5.36% 1.68 1.82 1.64
    Nov 17, 2023 1.66 0.13 8.50% 1.53 1.67 1.53
    Nov 16, 2023 1.55 -0.11 -6.63% 1.66 1.69 1.49
    Nov 15, 2023 1.66 0.18 12.16% 1.48 2.32 1.47
    Nov 14, 2023 1.30 0.03 2.36% 1.27 1.53 1.26
    Nov 13, 2023 1.30 -0.19 -12.75% 1.49 1.52 1.30
    Nov 10, 2023 1.48 -0.29 -16.38% 1.77 1.77 1.39

    Taysha Gene Therapies, Inc. Events

    Time (UTC) Country Event
    Tuesday, March 26, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Taysha Gene Therapies Inc Earnings Release
    Q4 2023 Taysha Gene Therapies Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total revenue 2.502 0 0 0
    Total Operating Expense 164.949 173.267 43.002 1.115
    Selling/General/Admin. Expenses, Total 37.36 41.324 11.109 0.128
    Research & Development 91.169 131.943 31.893 0.987
    Operating Income -162.447 -173.267 -43.002 -1.115
    Net Income Before Taxes -166.014 -174.523 -60.011 -1.115
    Net Income After Taxes -166.014 -174.523 -60.011 -1.115
    Net Income Before Extra. Items -166.014 -174.523 -60.011 -1.115
    Net Income -166.014 -174.523 -60.011 -1.115
    Income Available to Common Excl. Extra. Items -166.014 -174.523 -60.011 -1.115
    Income Available to Common Incl. Extra. Items -166.014 -174.523 -60.011 -1.115
    Diluted Net Income -166.014 -174.523 -60.011 -1.115
    Diluted Weighted Average Shares 43.952 37.6506 34.5214 34.5214
    Diluted EPS Excluding Extraordinary Items -3.77716 -4.63534 -1.73837 -0.0323
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -2.94853 -4.63534 -1.73837 -0.0323
    Interest Income (Expense), Net Non-Operating -3.549 -1.256 0.021
    Other, Net -0.018 0 -17.03
    Revenue 2.502
    Unusual Expense (Income) 36.42
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2.395 4.706 2.502 0 0
    Total Operating Expense 25.779 21.265 57.622 25.074 33.373
    Selling/General/Admin. Expenses, Total 5.988 8.751 7.341 8.683 9.867
    Research & Development 19.791 12.514 13.861 16.391 23.506
    Operating Income -23.384 -16.559 -55.12 -25.074 -33.373
    Interest Income (Expense), Net Non-Operating -1.217 -1.055 -0.597 -1.232 -0.716
    Other, Net 0.003 -0.008 -0.006 -0.001 -0.003
    Net Income Before Taxes -24.598 -17.622 -55.723 -26.307 -34.092
    Net Income After Taxes -24.598 -17.622 -55.723 -26.307 -34.092
    Net Income Before Extra. Items -24.598 -17.622 -55.723 -26.307 -34.092
    Net Income -24.598 -17.622 -55.723 -26.307 -34.092
    Income Available to Common Excl. Extra. Items -24.598 -17.622 -55.723 -26.307 -34.092
    Income Available to Common Incl. Extra. Items -24.598 -17.622 -55.723 -26.307 -34.092
    Diluted Net Income -24.598 -17.622 -55.723 -26.307 -34.092
    Diluted Weighted Average Shares 64.2445 63.2609 56.5228 40.9378 40.1424
    Diluted EPS Excluding Extraordinary Items -0.38288 -0.27856 -0.98585 -0.64261 -0.84928
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.38288 -0.27856 -0.34151 -0.64261 -0.84928
    Revenue 2.395 4.706 2.502 0
    Unusual Expense (Income) 36.42
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total Current Assets 96.417 159.602 257.879 0.015
    Other Current Assets, Total 1.172 1.408 0 0.015
    Total Assets 126.276 213.956 258.881 0.015
    Total Current Liabilities 62.79 51.746 7.129 0.15
    Accrued Expenses 18.287 29.983 5.135 0.15
    Notes Payable/Short Term Debt 0 0 0 0
    Total Liabilities 125.327 118.573 7.579 0.15
    Total Long Term Debt 37.967 37.192 0 0
    Total Equity 0.949 95.383 251.302 -0.135
    Additional Paid-In Capital 402.389 331.032 312.428 0.98
    Retained Earnings (Accumulated Deficit) -401.441 -235.649 -61.126 -1.115
    Total Liabilities & Shareholders’ Equity 126.276 213.956 258.881 0.015
    Total Common Shares Outstanding 63.2075 38.4739 34.5214 34.5214
    Cash and Short Term Investments 87.88 149.103 251.253
    Cash & Equivalents 87.88 149.103 251.253
    Prepaid Expenses 7.365 9.091 6.626
    Property/Plant/Equipment, Total - Net 25.906 50.61 0.287
    Other Long Term Assets, Total 3.953 3.744 0.715
    Accounts Payable 10.946 21.763 1.994
    Other Liabilities, Total 24.57 29.635 0.45
    Redeemable Preferred Stock 0 0 0
    Common Stock 0.001 0.00039 0.00035
    Other Equity, Total -0.00039 -0.00035
    Property/Plant/Equipment, Total - Gross 27.548 51.109
    Accumulated Depreciation, Total -1.642 -0.499
    Long Term Debt 37.967 37.192
    Other Current Liabilities, Total 33.557
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 171.807 54.115 72.358 96.417 43.002
    Cash and Short Term Investments 164.278 45.083 63.425 87.88 34.306
    Cash & Equivalents 164.278 45.083 63.425 87.88 34.306
    Prepaid Expenses 4.401 7.798 7.677 7.365 7.594
    Other Current Assets, Total 3.128 1.234 1.256 1.172 1.102
    Total Assets 195.769 81.543 101.6 126.276 111.468
    Property/Plant/Equipment, Total - Net 21.021 24.487 25.289 25.906 63.954
    Property/Plant/Equipment, Total - Gross 23.664 26.798 27.262 27.548 65.242
    Accumulated Depreciation, Total -2.643 -2.311 -1.973 -1.642 -1.288
    Other Long Term Assets, Total 2.941 2.941 3.953 3.953 4.512
    Total Current Liabilities 180.451 50.641 54.455 62.79 33.139
    Accounts Payable 7.52 10.766 9.002 10.946 15.251
    Accrued Expenses 12.612 18.611 15.584 18.287 17.888
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 244.883 118.657 116.548 125.327 100.342
    Total Long Term Debt 38.548 38.354 38.161 37.967 37.773
    Other Liabilities, Total 25.884 29.662 23.932 24.57 29.43
    Total Equity -49.114 -37.114 -14.948 0.949 11.126
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.002 0.001 0.001 0.001 0.001
    Additional Paid-In Capital 511.632 406.546 404.114 402.389 357.065
    Retained Earnings (Accumulated Deficit) -560.748 -443.661 -419.063 -401.441 -345.94
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 195.769 81.543 101.6 126.276 111.468
    Total Common Shares Outstanding 186.96 64.4326 63.4734 63.2075 41.1759
    Long Term Debt 38.548 38.354 38.161 37.967 37.773
    Other Current Liabilities, Total 159.974 20.927 29.541 33.557
    Current Port. of LT Debt/Capital Leases 0.345 0.337 0.328
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Net income/Starting Line -166.014 -174.523 -60.011 -1.115
    Cash From Operating Activities -88.39 -117.042 -30.729 0
    Non-Cash Items 56.619 28.322 29.384 0.98
    Changes in Working Capital 19.833 28.667 -0.111 0.135
    Net Change in Cash -61.223 -99.513 251.253 0
    Cash From Operating Activities 1.172 0.492 0.009
    Cash Interest Paid 2.775 0.641 0.028
    Cash From Investing Activities -24.93 -21.554 -9.082
    Capital Expenditures -20.619 -15.304 -0.082
    Other Investing Cash Flow Items, Total -4.311 -6.25 -9
    Cash From Financing Activities 52.097 39.083 291.064
    Issuance (Retirement) of Stock, Net 41.857 0 291.064
    Issuance (Retirement) of Debt, Net 0 39.957 0
    Financing Cash Flow Items 10.24 -0.874
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -17.622 -166.014 -110.291 -83.984 -50.317
    Cash From Operating Activities -20.185 -88.39 -102.667 -74.012 -40.939
    Cash From Operating Activities 0.331 1.172 0.808 0.531 0.26
    Non-Cash Items 1.803 56.619 15.806 11.107 6.773
    Changes in Working Capital -4.697 19.833 -8.99 -1.666 2.345
    Cash From Investing Activities -3.9 -24.93 -22.56 -19.54 -11.427
    Capital Expenditures -3.9 -20.619 -18.31 -16.29 -8.427
    Cash From Financing Activities -0.37 52.097 10.43 10.688 -0.107
    Issuance (Retirement) of Stock, Net 0.05 41.857 11.893 11.961 0.277
    Issuance (Retirement) of Debt, Net 0 0
    Net Change in Cash -24.455 -61.223 -114.797 -82.864 -52.473
    Cash Interest Paid 1.125 2.775 1.758 0.935 0.419
    Other Investing Cash Flow Items, Total 0 -4.311 -4.25 -3.25 -3
    Financing Cash Flow Items -0.42 10.24 -1.463 -1.273 -0.384
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Fidelity Management & Research Company LLC Investment Advisor 14.5263 27158335 -815211 2023-09-18 LOW
    Manning (Paul B.) Individual Investor 12.5255 23417778 0 2023-09-18 LOW
    RA Capital Management, LP Hedge Fund 9.8804 18472503 0 2023-09-18 LOW
    RTW Investments L.P. Investment Advisor/Hedge Fund 9.0357 16893185 16893185 2023-09-18 LOW
    VR Adviser, LLC Venture Capital 7.7259 14444444 0 2023-09-18 MED
    TCG Crossover Management, LLC Investment Advisor 5.943 11111111 0 2023-09-18 MED
    Session (R. A. II) Individual Investor 4.8962 9153927 0 2023-09-18 LOW
    Audentes Therapeutics Inc Corporation 3.8866 7266342 0 2023-08-16 LOW
    Stalfort (John A III) Individual Investor 1.0343 1933671 884290 2023-09-18 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.85 1589248 5810 2023-06-30 LOW
    Nolan Capital LLC Corporation 0.8213 1535545 444444 2023-09-18 MED
    Tybourne Capital Management (HK) Limited Hedge Fund 0.8023 1500000 0 2023-06-30 MED
    Invus Public Equities Advisors, LLC Investment Advisor 0.7707 1440882 0 2023-06-30 MED
    Nantahala Capital Management, LLC Hedge Fund 0.6692 1251139 -471261 2023-06-30 MED
    Laurion Capital Management LP Hedge Fund 0.6268 1171832 -120768 2023-06-30 HIGH
    Franklin Advisers, Inc. Investment Advisor/Hedge Fund 0.4337 810840 0 2023-06-30 LOW
    Sands Capital Ventures LLC Hedge Fund 0.3877 724873 0 2023-06-30 MED
    Alphabet, Inc. Venture Capital 0.3428 640882 0 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 0.3289 614938 137893 2023-06-30 HIGH
    Quantum Private Wealth, LLC Investment Advisor 0.2698 504380 145013 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Taysha Gene Therapies, Inc. Company profile

    About Taysha Gene Therapies Inc

    Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter; TSHA-102, which is being developed for the treatment of Rett syndrome; TSHA-103, which is being developed for the treatment of Solute Carrier Family 6 Member 1 (SLC6A1) haploinsufficiency disorder, and TSHA-104, which is being developed for the treatment for Surfeit locus 1.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Taysha Gene Therapies Inc revenues was not reported. Net loss increased from $41.7M to $124.1M. Higher net loss reflects Interest expense increase from $28K to $737K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.21 to -$3.30.

    Industry: Biotechnology & Medical Research (NEC)

    3000 Pegasus Park Drive
    Suite 1430
    DALLAS
    TEXAS 75247
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    71.01 Price
    -0.510% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    US100

    16,057.40 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    1,993.66 Price
    -0.620% 1D Chg, %
    Long position overnight fee -0.0199%
    Short position overnight fee 0.0117%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    BTC/USD

    42,432.60 Price
    -3.440% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading